The GAAD algorithm, combining AFP and PIVKA-II biomarker levels with age and gender (biological sex), was effective in distinguishing between HCC and benign CLD across all disease stages and etiologies assessed. The gene discussed is AFP; the disease is hepatocellular carcinoma.